• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zura Bio Limited

    5/2/24 5:58:36 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ZURA alert in real time by email
    SC 13G 1 tm2413405d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Zura Bio Limited

    (Name of Issuer)

     

    Class A Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G9TY5A101

    (CUSIP Number)

     

    April 22, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No.   G9TY5A101

    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    3,217,503

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    3,217,503

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,217,503

    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11

    Percent of Class Represented by Amount in Row (9)

     

    5.1%

    12

    Type of Reporting Person (See Instructions)

     

    IA, PN

     

     

     

    CUSIP No.   G9TY5A101

    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    3,217,503

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    3,217,503

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,217,503

    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11

    Percent of Class Represented by Amount in Row (9)

     

    5.1%

    12

    Type of Reporting Person (See Instructions)

     

    HC, IN

     

     

     

    CUSIP No.   G9TY5A101

    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    3,217,503

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    3,217,503

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,217,503

    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11

    Percent of Class Represented by Amount in Row (9)

     

    5.1%

    12

    Type of Reporting Person (See Instructions)

     

    HC, IN

     

     

     

    CUSIP No.   G9TY5A101

    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    3,217,503

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    3,217,503

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,217,503

    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11

    Percent of Class Represented by Amount in Row (9)

     

    5.1%

    12

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

    Item 1(a).Name of Issuer:

     

    Zura Bio Limited (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    1489 W. Warm Springs Rd. #110, Henderson, NV 89014

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships.

     

    Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Class A Ordinary Shares, par value $0.0001 per share (“Class A Ordinary Shares”)

     

    Item 2(e).CUSIP Number:

     

    G9TY5A101

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on April 23, 2024 and (ii) 20,090,128 Class A ordinary shares issued in the private placement of equity securities by the Issuer that closed on April 18, 2024 (the “Private Placement”).

     

    The Fund directly holds 3,217,503 Class A Ordinary Shares.

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the Issuer’s Class A Ordinary Shares reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: May 2, 2024

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By:/s/ Peter Kolchinsky  
    Name:Peter Kolchinsky  
    Title:Authorized Signatory  

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By:RA Capital Healthcare Fund GP, LLC  
    Its:General Partner  

     

    By:/s/ Peter Kolchinsky  
    Name:Peter Kolchinsky  
    Title:Manager  

     

     

     

    EXHIBIT 1

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of May 2, 2024 is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Class A Ordinary Shares, par value $0.0001 per share of Zura Bio Limited beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By:/s/ Peter Kolchinsky  
    Name:Peter Kolchinsky  
    Title:Authorized Signatory  

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By:RA Capital Healthcare Fund GP, LLC  
    Its:General Partner  

     

    By:/s/ Peter Kolchinsky  
    Name:Peter Kolchinsky  
    Title:Manager  

     

     

    Get the next $ZURA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZURA

    DatePrice TargetRatingAnalyst
    11/4/2024$15.00Outperform
    Leerink Partners
    9/5/2024$5.00Neutral
    H.C. Wainwright
    5/3/2024$26.00Overweight
    Piper Sandler
    10/10/2023$10.00Buy
    Ladenburg Thalmann
    8/25/2023$17.00Outperform
    Oppenheimer
    6/22/2023$20.00Buy
    Guggenheim
    6/14/2023$14.00Buy
    Chardan Capital Markets
    5/24/2023$20.00Strong Buy
    Raymond James
    More analyst ratings

    $ZURA
    Leadership Updates

    Live Leadership Updates

    See more
    • Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited

      8/13/24 9:21:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

      Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio's commitment to building leading immunology company as we prioritize excellence in strategic development and scientific planning Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equi

      3/28/24 6:00:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

      Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio's Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team. Mr. Lisicki will be responsible for developing an

      1/8/24 6:00:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 5:52:59 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 5:06:21 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Zura Bio Limited

      SC 13G - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 4:47:14 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    SEC Filings

    See more
    • Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      5/20/25 6:35:21 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zura Bio Limited

      SCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)

      5/15/25 5:43:13 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Zura Bio Limited

      SCHEDULE 13G - Zura Bio Ltd (0001855644) (Subject)

      5/14/25 4:11:09 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ploos Van Amstel Arnout bought $496,000 worth of Class A ordinary shares (80,000 units at $6.20), increasing direct ownership by 400% to 100,000 units (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      5/23/24 8:53:36 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Howell Michael bought $24,999 worth of Class A ordinary shares (7,987 units at $3.13) (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      4/24/24 6:54:25 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nistala Kiran bought $10,000 worth of Class A ordinary shares (3,195 units at $3.13) (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      4/24/24 6:53:25 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

      TibuSHIELD has launched with the activation of its first clinical site This study is the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in adults with moderate to severe hidradenitis suppurativa (HS) TibuSHIELD will assess tibulizumab over a 28-week study period, comprising a 16-week primary efficacy assessment and a 12-week safety follow-up, conducted at clinical sites across the United States, Canada, and Europe, with an optional open-label extension (OLE) Topline results for the primary efficacy endpoint at Week 16, along with key secondary and exploratory outcomes, are anticipated in the third quarter of 2026 Zura Bio

      5/20/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

      Advanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc) Continued preparations for the planned Phase 2 trial evaluating tibulizumab in adults with hidradenitis suppurativa (HS), expected to initiate in Q2 2025 Strengthened the team with a strategic appointment to support clinical execution and organizational growth $170.6 million in cash and cash equivalents with cash runway anticipated through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial resul

      5/8/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

      Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

      3/25/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Zura Bio Limited with a new price target

      Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

      11/4/24 7:45:03 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Zura Bio Limited with a new price target

      H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00

      9/5/24 8:35:06 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Zura Bio Limited with a new price target

      Piper Sandler initiated coverage of Zura Bio Limited with a rating of Overweight and set a new price target of $26.00

      5/3/24 7:45:08 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Financials

    Live finance-specific insights

    See more
    • Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

      Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

      3/25/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

      Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria

      11/7/24 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

      Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress

      11/13/23 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Badial Verender S.

      4 - Zura Bio Ltd (0001855644) (Issuer)

      5/12/25 4:15:32 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Technology Officer Whale Gary

      4 - Zura Bio Ltd (0001855644) (Issuer)

      3/3/25 5:03:45 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Nistala Kiran

      4 - Zura Bio Ltd (0001855644) (Issuer)

      3/3/25 5:02:54 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care